Abstract Objective: The objective of the study is to evaluate whether there is a difference in serum soluble free acid synthesis (sFas)/sFasL levels between patients with preeclampsia, severe preeclampsia and normal healthy pregnancy. Methods: This is a case control study comparing serum sFas and sFasL concentrations in patients with mild preeclampsia (n=26) and patients with severe preeclampsia (n=22) in the second and the third trimester pregnancy to normal healthy pregnant controls (n=21). Maternal serum sFas and sFasL was collected at the time of diagnosis of preeclampsia or severe preeclampsia and obtained using ELISA assay. The control group's characteristics of gestational age, maternal age, BMI, parity, smoking status, and history of hypertension were matched with the study groups. While evaluating the results, mean±SD for quantitaive data, the statistical methods of Kruskal Wallis and Mann-Whitney U tests for comparements between groups were used. Results: Maternal mean serum levels of sFas and sFasL were evaluated and statistical difference was not found in both preeclamptic pregnancies (846,65±96,74pg/ml and 17,48±15.60 pg/ml) and severe preeclamptic pregnancies ( 864,29±106,30 pg/ml and 99,92±336,69 pg/ml) versus control group (830,58±127,21 pg/ml and 30,13±22,69 pg/ml). For all demographic characteristics, there was also no statistical difference between study groups and control group. Conclusions: The finding of this study showed no difference in maternal serum levels of sFas and sFasL in preeclampsia and severe preeclampcia versus control group.
Abstract Objective: The objective of the study is to evaluate whether there is a difference in serum soluble free acid synthesis (sFas)/sFasL levels between patients with preeclampsia, severe preeclampsia and normal healthy pregnancy. Methods: This is a case control study comparing serum sFas and sFasL concentrations in patients with mild preeclampsia (n=26) and patients with severe preeclampsia (n=22) in the second and the third trimester pregnancy to normal healthy pregnant controls (n=21). Maternal serum sFas and sFasL was collected at the time of diagnosis of preeclampsia or severe preeclampsia and obtained using ELISA assay. The control group's characteristics of gestational age, maternal age, BMI, parity, smoking status, and history of hypertension were matched with the study groups. While evaluating the results, mean±SD for quantitaive data, the statistical methods of Kruskal Wallis and Mann-Whitney U tests for comparements between groups were used. Results: Maternal mean serum levels of sFas and sFasL were evaluated and statistical difference was not found in both preeclamptic pregnancies (846,65±96,74pg/ml and 17,48±15.60 pg/ml) and severe preeclamptic pregnancies ( 864,29±106,30 pg/ml and 99,92±336,69 pg/ml) versus control group (830,58±127,21 pg/ml and 30,13±22,69 pg/ml). For all demographic characteristics, there was also no statistical difference between study groups and control group. Conclusions: The finding of this study showed no difference in maternal serum levels of sFas and sFasL in preeclampsia and severe preeclampcia versus control group.